Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q1 CY2026 results topping the market’s revenue expectations, but sales fell by 2.3% year on year to $636.5 million. The company expects the full year’s revenue to be around $2.6 billion, close to analysts’ estimates. Its non-GAAP profit of $0.16 per share was significantly above analysts’ consensus estimates.
Is now the time to buy FTRE? Find out in our full research report (it’s free for active Edge members).
Fortrea (FTRE) Q1 CY2026 Highlights:
- Revenue: $636.5 million vs analyst estimates of $627.5 million (2.3% year-on-year decline, 1.4% beat)
- Adjusted EPS: $0.16 vs analyst estimates of $0.05 (significant beat)
- Adjusted EBITDA: $47 million vs analyst estimates of $34.61 million (7.4% margin, 35.8% beat)
- The company reconfirmed its revenue guidance for the full year of $2.6 billion at the midpoint
- EBITDA guidance for the full year is $205 million at the midpoint, above analyst estimates of $201.8 million
- Operating Margin: -0.5%, up from -79.9% in the same quarter last year
- Market Capitalization: $1.37 billion
StockStory’s Take
Fortrea’s first quarter results were well received by investors, as the company exceeded Wall Street expectations on both revenue and non-GAAP earnings. Management attributed this performance to improved commercial execution in its core clinical research services, especially a rebound in biotech client activity and a higher book-to-bill ratio for the third straight quarter. CEO Anshul Thakral emphasized the impact of deliberate efforts to diversify the customer base, with notable wins among early-stage and publicly listed biotech firms, while CFO Jill McConnell highlighted operational discipline and ongoing cost-optimization initiatives as key contributors to margin expansion.
Looking ahead, Fortrea expects ongoing progress toward its full-year margin and revenue goals, supported by continued pipeline strength and investments in technology. Management remains focused on advancing its new AI-enabled Fortrea Intelligent Technology (FIT) platform, which aims to accelerate clinical trial delivery and efficiency. CFO Jill McConnell indicated that future margin gains will depend on both sustained cost savings and measured investments in key talent and capabilities. CEO Anshul Thakral stated, “We believe our integrated, AI-enabled platform and operational discipline position us well to capitalize on a stabilizing market environment.”
Key Insights from Management’s Remarks
Management attributed the quarter’s results to a combination of improved biotech engagement, operational discipline, and early benefits from its technology investments.
-
Biotech client momentum: Fortrea saw a significant increase in requests for proposals and contract wins from biotech customers, particularly those developing new therapies in oncology, cardiovascular, and RNA-based areas. This diversification is a result of targeted commercial strategies and deeper engagement with emerging biotechs.
-
China market performance: The company reported strong double-digit growth in its China pipeline, reflecting both longstanding operational strength and new successes with strategic clients focused on global clinical trials. Management highlighted China as a growing contributor, with over 1,000 local employees supporting trial execution.
-
Launch of FIT platform: Fortrea introduced its AI-driven Fortrea Intelligent Technology (FIT), designed to automate workflows and enhance trial predictability. Early customer and partner feedback was positive, and management expects FIT to drive operational efficiency and differentiate Fortrea from peers over time.
-
Operational improvements: The company continued to streamline site activation processes and expand its global site navigator program, leading to faster trial start-up and more consistent site performance. These initiatives have improved customer experience, as evidenced by rising Net Promoter Scores.
-
Cost optimization progress: Fortrea achieved nearly $16 million in gross cost savings in the quarter, contributing to improved adjusted EBITDA margins. Management remains focused on balancing investments in people with maintaining financial discipline to support long-term growth.
Drivers of Future Performance
Fortrea’s outlook is shaped by improving biotech demand, ongoing technology adoption, and a disciplined approach to cost management.
-
Biotech and pharma demand trends: Management anticipates continued stabilization in large pharma and an accelerated recovery in biotech funding, resulting in a steadier flow of new clinical trial opportunities. This is expected to support a more consistent book-to-bill ratio and gradual revenue improvement over the coming quarters.
-
Technology and efficiency gains: The rollout of the FIT platform and embedded AI tools is expected to enhance operational efficiency and trial quality. However, management cautions that near-term benefits will be incremental, with larger efficiency gains and margin expansion likely to materialize over the next several years as adoption increases.
-
Cost discipline and measured investment: Fortrea will continue to implement cost optimization measures while making targeted investments in talent, therapeutic expertise, and commercial capabilities. Management indicated that these efforts are designed to support sustainable margin expansion and position the company for long-term competitiveness.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be monitoring (1) the continued pace and quality of biotech client wins and whether commercial traction remains robust; (2) early adoption and measurable impact of the FIT platform on operational efficiency and trial timelines; and (3) the realization of additional cost savings and margin gains as rightsizing initiatives mature. Sustained improvement in backlog conversion and any signs of changing competitive dynamics will also be important to track.
Fortrea currently trades at $14.54, up from $12.25 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.